Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 06 May 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 May 2014 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 02 May 2013 Planned end date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.